

We Claim:

1. A method of treating a patient suffering from viral  
5 hemorrhagic fever which comprises, administering to said  
patient a pharmaceutically effective amount of protein C.

2. The method of Claim 1 wherein the protein C is  
human protein C zymogen.

10 3. The method of Claim 1 wherein the protein C is  
human activated protein C.

15 4. The method according to Claim 3, wherein the amount  
of human activated protein C is about 1  $\mu\text{g}/\text{kg}/\text{hr}$  to about  
96  $\mu\text{g}/\text{kg}/\text{hr}$ .

20 5. The method of Claim 4, wherein the human activated  
protein C is administered by continuous infusion for about 1  
to about 240 hours.

25 6. A method of treating viral hemorrhagic fever in a  
patient in need thereof, which comprises administering to  
said patient a pharmaceutically effective amount of  
activated protein C such that an activated protein C plasma  
level of about 2 ng/ml to about 300 ng/ml is achieved.

30 7. The method of Claim 6 wherein the activated protein  
C is administered in a bolus injection.

PROSECUTION DRAFTING SHEET NO. 1

-18-

8. The method of Claim 6 wherein the activated protein C is administered by continuous infusion for about 1 to about 240 hours.

5 9. The method of Claim 6 wherein the activated protein C is administered first as a bolus then as a continuous infusion.

10 10. The method of Claim 9 wherein one third of the activated protein C required to achieve activated protein C plasma levels in the range of about 2 ng/ml to about 300 ng/ml is administered in a bolus injection followed by continuous infusion of the remaining two thirds of the activated protein C.

DISCLOSURE  
MADE BY  
SCHNEIDER